Prescott v. TC Heartland, LLC

Background

The parties asked the court to resolve TC Heartland’s discovery requests to Samuel Garcia concerning his pre-diabetes diagnosis and the treatment or management of his disease or symptoms. Garcia asserted claims, on behalf of himself and a proposed class, that TC Heartland had engaged in consumer fraud by advertising Splenda products as a healthy sugar alternative with positive health benefits, including for people with Type 2 diabetes.

Garcia’s class-certification declaration stated that he purchased several Splenda products in 2022 and 2023, relied on package statements that Splenda was the “#1 Recommended Brand by Doctors and Dietician” and “Suitable for People with Diabetes,” and believed the products were healthy alternatives to sugar. He also stated that he had been informed he was pre-diabetic and was looking for healthier alternatives to help manage his blood sugar and prevent progression to diabetes.

Discovery requests and objections

TC Heartland sought documents under Requests for Production 8 through 11 concerning Garcia’s diabetes treatment and management, blood glucose and hemoglobin A1C results, healthcare providers, medications, medical devices, supplements, and foods purchased or consumed to treat or manage diabetes or related symptoms.

Garcia objected that the requested information was irrelevant and disproportionate to the needs of the case, protected by the physician-patient privilege, and protected by the California Constitution’s privacy guarantee.

Court’s analysis

Under Federal Rule of Civil Procedure 26(b)(1), discovery may include nonprivileged information relevant to a claim or defense and proportional to the needs of the case. The court concluded that Garcia had placed his diagnosis and treatment plan at issue by tying his medical condition to his decision to purchase Splenda products. Those matters were relevant to materiality and reliance, which the court identified as elements of Garcia’s advertising claims.

The court did not authorize all discovery within Requests 8 through 11. It found no justification for discovery of all blood glucose or hemoglobin A1C test results, every medication, device, supplement, or food used to manage Garcia’s condition, or the names of all diabetes healthcare providers. Garcia had not placed the accuracy of his diagnosis or any physical harm from consuming Splenda at issue.

The court also found that Garcia had waived the physician-patient privilege for records reflecting or describing his diagnosis and treatment plan because he relied on those matters in his declaration and testified about them during his deposition. The opinion notes that the parties did not attach the cited deposition excerpts.

Regarding privacy, the court recognized Garcia’s interest in keeping his medical records confidential. It concluded that the limited scope of the permitted discovery, together with the existing protective order, adequately protected that interest.

Order

TC Heartland was entitled to obtain medical records reflecting or describing only:

1. Garcia’s pre-diabetes or diabetes diagnoses and symptoms; and 2. His healthcare providers’ treatment plans for treating or managing his disease or symptoms.

TC Heartland could not obtain other matters within Requests 8 through 11. Garcia could produce responsive records with the protections available under the protective order, including confidential treatment.